Assessing Responsiveness of Health Systems to Drug Safety Warnings

Lauren B. Gerlach, Hyungjin Myra Kim, Matheos Yosef, Anne E. Sales, Claire Stano, Helen C. Kales, Kara Zivin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: In 2011–2012 the U.S. Food and Drug Administration (FDA) issued safety announcements cautioning providers against prescribing high doses of citalopram given concerns for QT prolongation. The authors evaluated Veterans Affairs (VA) national trends in citalopram use and dose compared with alternative antidepressants after the FDA warnings. Methods: Time series analyses estimated the effect of the FDA warnings on citalopram and other antidepressant across three periods: before the first FDA warning in August 2011, after the 2011 FDA warning until the second warning in March 2012, and after the 2012 FDA warning. In a National VA health system, adult VA outpatients prescribed citalopram or alternative antidepressants from February 2010 to September 2013 were studied. Outpatient use of high-dose citalopram (>40 or >20 mg daily in adults aged > 60 years) including the proportion of patients prescribed citalopram and difference between study periods. Results: Between the first and second FDA warnings, among patients aged 18–60, high-dose citalopram use decreased by 2.0% per month (p < 0.001) and by 1.9% per month (p < 0.001) for older adults. After the second FDA warning in 2012, 30.7% of older patients remained on doses higher than the newly recommended dose of 20 mg. Reductions in overall use of citalopram were accompanied by significant increases in prescriptions of alternative antidepressants, with sertraline most widely prescribed. Conclusion: Although trends in high-dose citalopram use declined after the 2011–2012 FDA warnings, roughly one-third of older adults still remained on higher than recommended doses. Concomitant increases in sertraline and other antidepressant prescriptions suggest potential substitution of these medications for citalopram.

Original languageEnglish (US)
Pages (from-to)476-483
Number of pages8
JournalAmerican Journal of Geriatric Psychiatry
Volume26
Issue number4
DOIs
StatePublished - Apr 2018
Externally publishedYes

Fingerprint

Citalopram
United States Food and Drug Administration
Safety
Health
Pharmaceutical Preparations
Antidepressive Agents
Sertraline
Veterans
Prescriptions
Outpatients
Veterans Health

Keywords

  • antidepressants
  • Citalopram
  • FDA warning
  • QT prolongation

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Assessing Responsiveness of Health Systems to Drug Safety Warnings. / Gerlach, Lauren B.; Kim, Hyungjin Myra; Yosef, Matheos; Sales, Anne E.; Stano, Claire; Kales, Helen C.; Zivin, Kara.

In: American Journal of Geriatric Psychiatry, Vol. 26, No. 4, 04.2018, p. 476-483.

Research output: Contribution to journalArticle

Gerlach, Lauren B. ; Kim, Hyungjin Myra ; Yosef, Matheos ; Sales, Anne E. ; Stano, Claire ; Kales, Helen C. ; Zivin, Kara. / Assessing Responsiveness of Health Systems to Drug Safety Warnings. In: American Journal of Geriatric Psychiatry. 2018 ; Vol. 26, No. 4. pp. 476-483.
@article{0e0633659ebc4d3586205f81a1fcce7a,
title = "Assessing Responsiveness of Health Systems to Drug Safety Warnings",
abstract = "Objective: In 2011–2012 the U.S. Food and Drug Administration (FDA) issued safety announcements cautioning providers against prescribing high doses of citalopram given concerns for QT prolongation. The authors evaluated Veterans Affairs (VA) national trends in citalopram use and dose compared with alternative antidepressants after the FDA warnings. Methods: Time series analyses estimated the effect of the FDA warnings on citalopram and other antidepressant across three periods: before the first FDA warning in August 2011, after the 2011 FDA warning until the second warning in March 2012, and after the 2012 FDA warning. In a National VA health system, adult VA outpatients prescribed citalopram or alternative antidepressants from February 2010 to September 2013 were studied. Outpatient use of high-dose citalopram (>40 or >20 mg daily in adults aged > 60 years) including the proportion of patients prescribed citalopram and difference between study periods. Results: Between the first and second FDA warnings, among patients aged 18–60, high-dose citalopram use decreased by 2.0{\%} per month (p < 0.001) and by 1.9{\%} per month (p < 0.001) for older adults. After the second FDA warning in 2012, 30.7{\%} of older patients remained on doses higher than the newly recommended dose of 20 mg. Reductions in overall use of citalopram were accompanied by significant increases in prescriptions of alternative antidepressants, with sertraline most widely prescribed. Conclusion: Although trends in high-dose citalopram use declined after the 2011–2012 FDA warnings, roughly one-third of older adults still remained on higher than recommended doses. Concomitant increases in sertraline and other antidepressant prescriptions suggest potential substitution of these medications for citalopram.",
keywords = "antidepressants, Citalopram, FDA warning, QT prolongation",
author = "Gerlach, {Lauren B.} and Kim, {Hyungjin Myra} and Matheos Yosef and Sales, {Anne E.} and Claire Stano and Kales, {Helen C.} and Kara Zivin",
year = "2018",
month = "4",
doi = "10.1016/j.jagp.2017.09.024",
language = "English (US)",
volume = "26",
pages = "476--483",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Assessing Responsiveness of Health Systems to Drug Safety Warnings

AU - Gerlach, Lauren B.

AU - Kim, Hyungjin Myra

AU - Yosef, Matheos

AU - Sales, Anne E.

AU - Stano, Claire

AU - Kales, Helen C.

AU - Zivin, Kara

PY - 2018/4

Y1 - 2018/4

N2 - Objective: In 2011–2012 the U.S. Food and Drug Administration (FDA) issued safety announcements cautioning providers against prescribing high doses of citalopram given concerns for QT prolongation. The authors evaluated Veterans Affairs (VA) national trends in citalopram use and dose compared with alternative antidepressants after the FDA warnings. Methods: Time series analyses estimated the effect of the FDA warnings on citalopram and other antidepressant across three periods: before the first FDA warning in August 2011, after the 2011 FDA warning until the second warning in March 2012, and after the 2012 FDA warning. In a National VA health system, adult VA outpatients prescribed citalopram or alternative antidepressants from February 2010 to September 2013 were studied. Outpatient use of high-dose citalopram (>40 or >20 mg daily in adults aged > 60 years) including the proportion of patients prescribed citalopram and difference between study periods. Results: Between the first and second FDA warnings, among patients aged 18–60, high-dose citalopram use decreased by 2.0% per month (p < 0.001) and by 1.9% per month (p < 0.001) for older adults. After the second FDA warning in 2012, 30.7% of older patients remained on doses higher than the newly recommended dose of 20 mg. Reductions in overall use of citalopram were accompanied by significant increases in prescriptions of alternative antidepressants, with sertraline most widely prescribed. Conclusion: Although trends in high-dose citalopram use declined after the 2011–2012 FDA warnings, roughly one-third of older adults still remained on higher than recommended doses. Concomitant increases in sertraline and other antidepressant prescriptions suggest potential substitution of these medications for citalopram.

AB - Objective: In 2011–2012 the U.S. Food and Drug Administration (FDA) issued safety announcements cautioning providers against prescribing high doses of citalopram given concerns for QT prolongation. The authors evaluated Veterans Affairs (VA) national trends in citalopram use and dose compared with alternative antidepressants after the FDA warnings. Methods: Time series analyses estimated the effect of the FDA warnings on citalopram and other antidepressant across three periods: before the first FDA warning in August 2011, after the 2011 FDA warning until the second warning in March 2012, and after the 2012 FDA warning. In a National VA health system, adult VA outpatients prescribed citalopram or alternative antidepressants from February 2010 to September 2013 were studied. Outpatient use of high-dose citalopram (>40 or >20 mg daily in adults aged > 60 years) including the proportion of patients prescribed citalopram and difference between study periods. Results: Between the first and second FDA warnings, among patients aged 18–60, high-dose citalopram use decreased by 2.0% per month (p < 0.001) and by 1.9% per month (p < 0.001) for older adults. After the second FDA warning in 2012, 30.7% of older patients remained on doses higher than the newly recommended dose of 20 mg. Reductions in overall use of citalopram were accompanied by significant increases in prescriptions of alternative antidepressants, with sertraline most widely prescribed. Conclusion: Although trends in high-dose citalopram use declined after the 2011–2012 FDA warnings, roughly one-third of older adults still remained on higher than recommended doses. Concomitant increases in sertraline and other antidepressant prescriptions suggest potential substitution of these medications for citalopram.

KW - antidepressants

KW - Citalopram

KW - FDA warning

KW - QT prolongation

UR - http://www.scopus.com/inward/record.url?scp=85031731895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031731895&partnerID=8YFLogxK

U2 - 10.1016/j.jagp.2017.09.024

DO - 10.1016/j.jagp.2017.09.024

M3 - Article

C2 - 29066038

AN - SCOPUS:85031731895

VL - 26

SP - 476

EP - 483

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 4

ER -